Merz Aesthetics Launches New Belotero® Lips Dermal Filler Products
Merz, a global leader in medical aesthetics, today announced the launch of Belotero® Lips, with products specifically designed for lip enhancement and treatment of perioral lines. The line includes two hyaluronic acid (HA) dermal filler products that complement each other to deliver safe, effective and natural-looking cosmetic results.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180409005702/en/
Belotero Lips Shape and Contour (Graphic: Business Wire)
Popularized by celebrities and social media influencers, the lip-filler market for female millennials is on the fast track to growth: lip beautification with hyaluronic acid fillers is currently among the most frequently requested procedures in aesthetic practices1. Designed to appeal to a broader and more youthful target audience, the new Belotero® Lips campaign emphasizes the importance of individual beauty and emotions with the tagline “Showing off not just you - but an enhanced version of you.” Most importantly, Belotero® Lips gives aesthetic physicians more creative power with two new products that can be tailored to meet every individual patient's needs and desires.
“A single product is often not versatile enough to deliver the natural, personalized result desired by lip patients,” said Dr. Yannick Grosskreutz, Vice President and Head of Global Marketing for Merz. “With the launch of Belotero® Lips Shape and Contour, Merz is proud to now offer physicians a unique complementary approach to lip enhancement.”
Modern female consumers already know what it means to “get their lips done.” As a result they have high expectations: results need to be natural, long-lasting and comfortable, and lip treatment is seen as a way to show off their own enhanced yet unique beauty. Just as lipstick and lipliner complement each other, Belotero® Lips Shape and Belotero® Lips Contour provide volume and definition for patient-specific, optimized results. Belotero® Lips Shape is intended for lip augmentation and enhancing the upper and lower lip, while Belotero® Lips Contour is designed to define the outline of the lip.
“Full, well-defined lips are a key signature of youth and beauty. That is why in my practice, I often see patients looking to enhance their smile and to address the signs of aging in this crucial area of the face,” said Dr. Uliana Gout, Cosmetic Doctor and Founder of London Aesthetic Medicine, UK. “Belotero® Lips is positioned for good tissue integration, delivery of high patient satisfaction and natural-looking results for all ages. Due to the extra versatility offered by the Belotero® Lips concept, with products specifically designed for both shaping and contouring, this allows for a tailored lip treatment for our patients.”
Lip augmentation using Belotero® Lips Shape and Belotero® Lips Contour was clinically assessed in a retrospective, multicenter study involving 146 patients.2 Observation period took place over 4 months, with assessment of handling and treatment results. For CPM-HAL2, the outcome with regard to naturalness and evenness after 2 weeks was assessed by the vast majority as very good (87%). This very good assessment was still maintained for 66.7% of patients after 4 months. The most common side effects observed following lip treatment with Belotero® were: swelling, tenderness, bruising, pain and redness. The majority of these side effects were mild and have also been observed in other lip enhancement clinical trials. Belotero® Lips Shape and Belotero® Lips Contour should only be administered by a physician or qualified healthcare professional.
Belotero® Lips products are now available in select countries in Europe, with additional markets to be added later this year. For more details, please visit https://global.belotero.com/ or follow @Merz_Aesthetics on Instagram.
With approximately 3,000 employees and a direct presence in 28 countries, Merz is a global, family-owned medical aesthetics and neurotoxin company based in Frankfurt, Germany. Privately held for 110 years, the company is distinguished by its commitment to innovation, solid financial strength and continuous growth. In addition to its comprehensive portfolio of medical aesthetic products in the device, injectable and skincare categories, Merz also develops neurotoxin therapy to treat neurologically-induced movement disorders. In fiscal year 2016/17, Merz generated revenue of EUR 1,092.9 million. More information is available at www.merz.com.
1 Sarnoff DS, Gotkin RH. Six steps to the “perfect” lip. J Drugs Dermatol. 2012 Sep;11(9):1081-8.
2 Fischer TC, et al. Hyaluron Filler Containing Lidocaine on a CPM Basis for Lip Augmentation: Reports from Practical Experience. Facial Plast Surg. 2016 Jun;32(3):283-8.
Merz Pharma GmbH & Co. KGaA
Global Corporate Communications
Mariana Smith Bourland
Phone: +49 151 4249 1466
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ZephyrTel Welcomes Vasona to Its Portfolio of Software Solutions Serving the Global Telecommunications Sector26.9.2018 10:01 | Pressemelding
ZephyrTel, an ESW Capital software company dedicated to serving the global telecommunications industry, is pleased to announce it has acquired Vasona Networks, a leader in network performance and edge computing software for mobile operators, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180926005376/en/ Mike Shinya, CEO of ZephyrTel (Photo: Business Wire) ZephyrTel is building a world-class telco practice, to provide a multi-solution and services proposition to the global telco industry and leading enterprises. The company’s primary objective is to offer software and SaaS solutions across telco companies IT estates; from infrastructure right through to customer experience. This, coupled with high levels of industry domain expertise, will enable it to offer consultancy on both business strategy and technology execution. Having already acquired several telecom software companies, ZephyrTel is currently
Hallstar Names Scott Hinkle as New Chief Financial Officer and Head of Global Shared Services26.9.2018 10:00 | Pressemelding
Scott J. Hinkle has joined Hallstar, the global specialty chemistry company, as Chief Financial Officer. He will be based in Hallstar’s corporate headquarters in Chicago, Illinois, reporting directly to Chairman and CEO, John J. Paro. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180926005216/en/ Hallstar Names Scott Hinkle as New Chief Financial Officer and Head of Global Shared Services (Photo: Business Wire) Founded in 1986, Hallstar has become widely recognized for its innovative expertise in the areas of photostability science, renewable plasticizers, eco-based actives, phthalate replacements, natural olive chemistry and polymer modification. The company boasts research and development, manufacturing, and sales operations in China, Italy, France, and Brazil, in addition to the United States. Hallstar recently announced a structural split into Hallstar Beauty and Hallstar Industrial, effective October 1, 2018. These two
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC26.9.2018 08:00 | Pressemelding
Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make informed decisions on how to sequence treatments for patients with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC). The survey results will be presented today as a late-breaking abstract (P3.01-108) at the 2018 World Conference on Lung Cancer (WCLC) in Toronto, Canada. The two most important treatment goals identified by those surveyed were increasing overall survival (OS) (77%), followed by quality of life (QoL) (69%), irrespective of the line of treatment. Findings show that more than half (55%) of physicians strongly preferred a treatment sequence that offers patients the maximum time on targeted treatments. Furthermore, physicians reported that there is a strong need for information on potential treatment resistance mutations before changing their current treatment pract
Easy Visual Launches App For Targeted Advertising Reach Through Smartphones26.9.2018 07:00 | Pressemelding
Easy Visual has launched Banners App - a mobile application that shows targeted banners ads to users when they unlock their smartphones. Recent Boston Consulting Group research indicates that consumers spend 25% of their total offline and online media consumption time on mobile phones. However, advertisers spend only 12% of their budgets on mobile ads. Mobile advertising is unappreciated by some brands and it results in a loss of potential clients. Easy Visual has decided to change the situation. 69% of consumers from 18 to 39 years old use smartphones to look for products before buying them. Banners App offer brands and advertisers ads shown only to their target audiences, real views, statistics on the number of views and the conversion rate. Companies get potential customers, brand recognition and better ROI. It avoids brand reputational loss, because users voluntarily look at the advertising messages. Easy Visual is an innovative advertising network that provides advertisers and bra
SoftAtHome Invests in Quality of Experience for Fixed-Mobile Convergence by Acquiring V3D, Leader in Telecom Data Analytics26.9.2018 07:00 | Pressemelding
SoftAtHome, the software company dedicated to the digital home, and V3D, a leading independent software vendor expert on Telecom data analytics for carrier network operators, announced today the signing of an acquisition agreement. With SoftAtHome acquiring V3D, the company will be able to deliver a full range of solutions around “analytics for Quality of Experience” for its fixed and mobile operator clients, by relying on the millions of data points collected by V3D. Thanks to both companies’ expertise, skills and solutions, Carrier Network Operators will benefit from a global value proposition on improving Customer Experience on their fixed and mobile networks. David VIRET-LANGE, Chief Executive Officer of SoftAtHome, commented: “In an increasingly digital world, consumers expect seamless connectivity with their mobile and tablets wherever they are. Quality of Experience will be naturally measured by the same solutions. The V3D solution portfolio and expertise on mobile and fixed net
NeoTract Announces Results from Five Real-World Studies Reaffirming Efficacy and Safety of UroLift® System Treatment for Enlarged Prostate26.9.2018 06:05 | Pressemelding
NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of Endourology 2018 Annual Conference from five studies of the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH). “The real-world results from these studies of diverse patient populations on three continents reaffirm the sustained benefits of the UroLift System as an accepted standard of care treatment for patients with BPH,” said Dave Amerson, president of the NeoTract Interventional Urology business unit. “We are pleased that we continue to see results from real-world studies in line with our randomized pivotal study, demonstrating that the UroLift System is a safe and effective minimally invasive treatment that offers men long-term relief from the symptoms of BPH.” Five Studies Show Significant Relief and Improved Quality of Life with UroLift Sy